At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Market Closed 10-23 16:00:00 EDT
8.65
-0.17
-1.93%
盘后8.65
+0.000.00%
16:14 EDT
High8.91Low8.53Vol158.39K
Open8.91D1 Closing8.82Amplitude4.31%
Mkt Cap301.74MTradable Cap159.62MTotal Shares34.88M
T/O1.38MT/O Rate0.86%Tradable Shares18.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Raymond James Initiates Coverage on Benitec Biopharma With Outperform Raring, $14 PT
MT Newswires Live  ·  10-23 19:26
Raymond James Initiates Coverage on Benitec Biopharma With Outperform Raring, $14 PT
Benitec Biopharma Inc : Raymond James Initiates Coverage with Outperform Rating; Target Price $14
THOMSON REUTERS  ·  10-23 19:22
Benitec Biopharma Inc : Raymond James Initiates Coverage with Outperform Rating; Target Price $14
US Research Roundup- Amgen, Lockheed Martin, Norfolk Southern
Reuters  ·  10-23 15:54
US Research Roundup- Amgen, Lockheed Martin, Norfolk Southern
FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated
TIPRANKS  ·  10-06
FDA Clarity on BB-301 Phase 3 Supports Buy Rating on BNTC; $17 Price Target Reiterated
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
TIPRANKS  ·  10-05
Benitec Biopharma says BB-301 pivotal still on track for mid-2027
Benitec Biopharma Targets Mid-2027 Start for BB-301 Pivotal Trial in OPMD Dysphagia
Reuters  ·  10-05
Benitec Biopharma Targets Mid-2027 Start for BB-301 Pivotal Trial in OPMD Dysphagia
Benitec Biopharma - Patient Enrollment for Bb-301 Pivotal Study Planned to Begin in Mid-2027
THOMSON REUTERS  ·  10-05
Benitec Biopharma - Patient Enrollment for Bb-301 Pivotal Study Planned to Begin in Mid-2027
Benitec Biopharma - FDA Requests Additional Data for Bb-301 Pivotal Study Including Opmd Natural History Study Data
THOMSON REUTERS  ·  10-05
Benitec Biopharma - FDA Requests Additional Data for Bb-301 Pivotal Study Including Opmd Natural History Study Data
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for Bb-301 Pivotal Study
THOMSON REUTERS  ·  10-05
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for Bb-301 Pivotal Study
Benitec Biopharma - Final Bb-301 Pivotal Study Design Expected to be Confirmed in 1Q 2027
THOMSON REUTERS  ·  10-05
Benitec Biopharma - Final Bb-301 Pivotal Study Design Expected to be Confirmed in 1Q 2027
Benitec Biopharma Inc - Timelines for Bb-301 Pivotal Study Remain on Track
THOMSON REUTERS  ·  10-05
Benitec Biopharma Inc - Timelines for Bb-301 Pivotal Study Remain on Track
Benitec Biopharma Appoints Ernst & Young as Independent Auditor for Fy2027
Reuters  ·  10-01
Benitec Biopharma Appoints Ernst & Young as Independent Auditor for Fy2027
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Benitec Biopharma (BNTC)
TIPRANKS  ·  09-28
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Benitec Biopharma (BNTC)
Benitec Biopharma Switches Auditor to Ernst & Young from Baker Tilly
Reuters  ·  09-25
Benitec Biopharma Switches Auditor to Ernst & Young from Baker Tilly
BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating
TIPRANKS  ·  09-16
BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating
Benitec Biopharma price target raised to $17 from $16 at Wedbush
TIPRANKS  ·  09-15
Benitec Biopharma price target raised to $17 from $16 at Wedbush
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)
TIPRANKS  ·  09-15
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)
Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating
MT Newswires Live  ·  09-15
Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating
Benitec Biopharma Files $200 Million Shelf Registration
MT Newswires Live  ·  09-15
Benitec Biopharma Files $200 Million Shelf Registration
Benitec Biopharma files $200M mixed securities shelf
TIPRANKS  ·  09-15
Benitec Biopharma files $200M mixed securities shelf

Introduction

Company Name.
Benitec Biopharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Issue price:
--